Viatris And Sandoz May Market Injectafer Generic In US From 2026

ANDA Disputes Regarding Ferric Carboxymaltose Are Now Settled

 
• By Chloe Kent

After over two years of litigation, Vifor and American Regent have reached agreements with Viatris’ Mylan and Sandoz regarding their generic ferric carboxymaltose products, allowing both companies to bring rivals to market ahead of the expiry of certain US patents.

2026 sign
Viatris’ Mylan unit and Sandoz will have licenses to market generic ferric carboxymaltose products in the US from 1 July 2026 • Source: Alamy

More from Generics

More from Products